Vitamin D and Telomeres: What the VITAL Trial Found — Dr JoAnn Manson
In the Harvard-led VITAL trial, a subgroup analysis found that participants taking 2,000 IU of vitamin D daily showed only about one year of telomere shortening over four years, while the placebo group showed the full four years. Dr JoAnn Manson explains the likely inflammation link, the parallel findings on autoimmune disease and advanced cancer, and why body mass index appears to blunt the effect.
Overview
VITAL is a nationwide randomized trial of more than 25,000 US adults — men 50+ and women 55+ — testing 2,000 IU of vitamin D and one gram of omega-3s daily against placebo in a two-by-two factorial design, with an average follow-up of 5.3 years. Its primary aims were cardiovascular disease and cancer prevention, but an ancillary study in 1,054 Boston-area participants collected carefully processed blood samples that allowed researchers to measure telomere length and inflammatory markers.
Published in the American Journal of Clinical Nutrition in May 2025, that analysis found roughly one year of leukocyte telomere shortening in the vitamin D group over four years, versus four years of shortening on placebo. Omega-3s trended in a protective direction but did not reach significance on their own, and there was no clear additive effect. Dr Manson describes telomeres as the protective caps at the ends of chromosomes — like the tips on a shoelace — that shorten as cells replicate and are considered one biological pathway of aging.
The leading hypothesis for the vitamin D effect is anti-inflammatory: VITAL also showed lower high-sensitivity C-reactive protein, a 22% reduction in a composite autoimmune disease outcome, and a 17% reduction in advanced (metastatic or fatal) cancers. Across all of these outcomes, body mass index modified the response — benefits concentrated in people at a healthy weight and were blunted above a BMI of 30, even at higher doses in other trials. Manson is careful to note the underlying mechanism remains unproven and was never an original aim of VITAL.
Key quotes
5Over 4 years of treatment, there was only 1 year of telomere shortening in the vitamin D randomized group, in comparison to the placebo group that had 4 years of telomere shortening.
One way to think about the telomeres is that they're the protective caps at the end of the chromosome, similar to the protective caps on shoelaces that keep the shoelace from unraveling.
It may be that the benefit of vitamin D in reducing inflammation, lowering CRP levels, reducing autoimmune diseases, may also be protecting the telomeres.
The participants who benefit the most from the vitamin D supplements are those in the healthy weight range, and those with a BMI especially above 30 did not derive the same benefits.
The participants who were in the trial for at least one to two years had close to a 40% reduction in autoimmune disease, suggesting there's a latency period.
Key ideas
9What VITAL actually tested
A nationwide randomized trial in over 25,000 midlife and older US adults, comparing 2,000 IU of vitamin D and one gram of omega-3s daily against placebo. Participants were generally healthy and not selected for any specific condition, making it a primary prevention study.
A two-by-two factorial design
Four arms — vitamin D alone, omega-3s alone, both together, and dual placebo — let the team read each supplement independently. On telomeres, vitamin D carried the signal; omega-3s trended protective without reaching significance and added no clear extra benefit.
Four years of aging compressed into one
In the Boston sub-cohort with repeat blood draws, the placebo group showed four years of leukocyte telomere shortening while the vitamin D group showed roughly one. The analysis included over 900 participants with baseline plus a two- or four-year follow-up sample.
Telomeres as one pathway, not the whole story
Telomere shortening is one biological pathway of aging alongside others such as DNA methylation and epigenetic clocks. Shorter telomeres track with higher risk of cardiovascular disease, type 2 diabetes and osteoporotic fracture, though the cancer literature is genuinely mixed.
Inflammation as the likely bridge
VITAL showed 2,000 IU lowered high-sensitivity CRP and several other inflammatory markers. Since chronic systemic inflammation rises with age and may accelerate telomere loss during cell replication, damping inflammation is the leading explanation for the telomere finding.
A 17% reduction in advanced cancers
Total incident cancer was not significantly reduced, but metastatic plus fatal cancers fell by 17%. Manson suggests vitamin D may influence invasiveness and progression rather than the initial development of a first cancer.
Why 2,000 IU and not more
That dose brought average 25-hydroxy vitamin D to about 40 ng/mL (100 nmol/L), the range where epidemiologic risk curves flatten. Testing 4,000 IU was avoided because it sits at the tolerable upper intake level once diet and personal supplements are added on top.
BMI as the gatekeeper
Across telomeres, autoimmune outcomes and other endpoints, benefit concentrated in people at a healthy weight and was blunted above a BMI of 30 — even at 4,000 IU in the separate D2D trial. Blood-level differences were too small to explain it, pointing toward receptor-level resistance.
The 22% autoimmune signal
A separate VITAL analysis published in the BMJ found a 22% reduction in a composite of autoimmune conditions including rheumatoid arthritis, psoriasis, multiple sclerosis and lupus. The effect grew with longer treatment, approaching 40% among those on trial for at least one to two years.
Practical takeaways
6- 1
Read the result as a rate, not a reversal 9:40
Nothing in VITAL lengthened telomeres — the vitamin D group simply lost less. When you see "three years of aging frozen," it describes a slower rate of shortening over four years, not turning back a clock.
- 2
2,000 IU was the tested amount 36:00
This is the dose with randomized four- and five-year data behind it, producing blood levels around 40 ng/mL. Higher is not automatically better; the epidemiologic curves plateau above that range.
- 3
Body composition may change what you get 41:30
If your BMI is above 30, the same dose appears to deliver less benefit across several VITAL outcomes. That is a reason to discuss dose and form with your own clinician rather than assume a standard amount applies.
- 4
25-hydroxy vitamin D is the marker worth knowing 44:00
It has a multi-week half-life and reflects your status stably, unlike the biologically active form, which is tightly regulated and can look normal even during real deficiency.
- 5
Give it time 47:20
The autoimmune benefit grew with duration, approaching 40% after one to two years in the trial. Biological pathway effects here are measured in years, not weeks.
- 6
Bone health and healthspan are different questions 50:30
VITAL found no clear fracture or bone density benefit from the extra 2,000 IU, consistent with 600–800 IU being enough for bone. The interesting signals sat elsewhere — inflammation, autoimmunity, advanced cancer, telomeres.
Topics & chapters
15Why this trial made headlines
The framing of the finding: telomere preservation equivalent to as much as three years of biological aging over a four-year window.
Introducing VITAL
A nationwide randomized trial of vitamin D and omega-3s in more than 25,000 generally healthy midlife and older US adults.
The Boston sub-cohort
1,054 participants gave optimally processed blood samples so telomeres and inflammatory markers could be measured; over 900 had follow-up draws.
Four arms, read independently
The two-by-two factorial design and why vitamin D — not omega-3s — carried the telomere signal.
The headline result
One year of telomere shortening on vitamin D versus four years on placebo, published in the American Journal of Clinical Nutrition in May 2025.
How telomeres were measured
Peripheral blood leukocytes, a technically demanding assay, and the shoelace-cap analogy for what a telomere does.
What shortens telomeres
Cell replication as the underlying driver, and telomere loss as one of several biological pathways of aging.
The cancer nuance
Shorter telomeres track with cardiovascular disease and diabetes risk, but the cancer relationship is inconsistent — melanoma being a notable surprise.
The inflammation hypothesis
Lower CRP, fewer autoimmune events, and the idea that damping chronic inflammation protects telomeres during replication.
Advanced cancer and cell replication
A 17% reduction in metastatic plus fatal cancers, and the alternative mechanism of vitamin D influencing proliferation and invasiveness.
Telomerase and the limits of what's known
An earlier collaborator's trial suggested effects on telomerase activity, but Manson stresses the mechanism is unproven and outside VITAL's original aims.
Why 2,000 IU was chosen
Target blood levels around 40 ng/mL, the plateau in epidemiologic risk curves, and the Institute of Medicine's 4,000 IU upper intake level.
BMI, receptors and calcifediol
Why benefit concentrates below a BMI of 30, why blood levels don't explain it, and the interest in liver-metabolized forms of vitamin D.
The autoimmune findings
A 22% reduction in a composite autoimmune outcome published in the BMJ, rising toward 40% with longer treatment.
Bone health, guidelines and what's next
No clear fracture benefit, where guideline bodies currently stand, and continued follow-up plus epigenetic clock work at vitalstudy.org.